Received:18 January 2023Accepted:28 February2023D0L:10.1111/dme.15078DIABETICPOSITION STATEMENTMedicineUK's Association of British Clinical Diabetologist's DiabetesTechnology Network (ABCD-DTN):Best practice guide forhybrid closed-loop therapyTomas P.Griffin1234 Geraldine Gallens Sara Hartnells Thomas Crabtree7sMelissa Holloway Fraser W.Gibbl0 Alistair Lumb112 Emma G.Wilmot78Pratik Choudhary 2 Sufyan Hussain13.14Leicester Diabetes Centre,University Hospitals of Leicester,Leicester,UKDiabetes Research Centre,College of Health Sciences,University of Leicester,Leicester,UKSchool of Medicine,University of Limerick,Limerick,IrelandCentre for Diabetes and Endocrinology,University Hospital Limerick,Limerick,IrelandSDepartment of Diabetes,School of Cardiovascular,Metabolic Medicine and Sciences,King's College London,London,UKDepartment of Diabetes and Endocrinology,Cambridge University Hospitals NHS Foundation Trust,Cambridge,UKUniversity Hospitals of Derby and Burton NHS Foundation Trust,Derby,UKTranslational Medical Sciences,University of Nottingham,Nottingham,UKExpert by Experience,Independent Consultant,London,UKEdinburgh Centre for Endocrinology&Diabetes,Royal Infirmary of Edinburgh,Edinburgh,UKOxford Centre for Diabetes,Endocrinology and Metabolism,Oxford,UKOxford NIHR Biomedical Research Centre,Oxford,UKDepartment of Diabetes,School of Cardiovascular,Metabolic Medicine and Sciences,King's College London,London,UKDepartment of Diabetes and Endocrinology,Guy's&StThomas'NHS Foundation Trust,London,UKCorrespondenceSufyan Hussain,Department ofAbstractDiabetes,School of Cardiovascular,This best practice guide is written with the aim of providing an overview of cur-Metabolic Medicine and Sciences,rent hybrid closed-loop(HCL)systems in use within the United Kingdom's(UK)King's College London,Great MazePond.London SE1 9RT.UK.National Health Service (NHS)and to provide education and advice for theirEmail:sufyan.hussain@kcl.ac.ukmanagement on both an individual and clinical service level.The environment ofdiabetes technology,and particularly HCL systems,is rapidly evolving.The pastdecade has seen unprecedented advances in the development of HCL systems.These systems improve glycaemic outcomes and reduce the burden of treatmentfor people with type 1 diabetes (pwT1D).It is anticipated that access to thesesystems will increase in England as a result of updates in National Institute ofHealth and Care Excellence (NICE)guidance providing broader support for theuse of real-time continuous glucose monitoring(CGM)for pwTID.NICE is cur-rently undertaking multiple-technology appraisal into HCL systems.Based onThis isan open access article under the termsof the Creative Commons Attribution License.which permitsuse.distribution and eproduction in any medium.pvidedthe original work is properly cited.2023 The Authors.Diaberic Medicine published by John Wiley Sons Ltd on behalf of Diabetes UK.Diaberic Medicine.2023:00e15078.wileyonlinelibrarycom/joumal/dme 1 of 21https://do
